ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2026

Abstract Number: 0105

Gene expression signatures as predictors of response to methotrexate in pediatric non-infectious uveitis (NIU).

Grant Schulert1, Thuy Do1, Ashley Kuenzi Davis1, Emily Straus1, Abigale Jagger2, Margaret Chang3, Mekibib Altaye4, Virginia Utz1, Hermine Brunner1, Andrew Zeft5, Sunil Srivastava6, Erin Stahl7, Ashley Cooper7, Bharti Nihalani-Gangwani8, Mindy Lo9, Megan Quinlan-Waters1, Alexandra Duell1 and Sheila Angeles-Han10

Affiliations: 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's, Cincinnati, OH, 3Boston Children's Hospital, Newton, MA, 4Cincinnati Children's Hospital, Cincinnati, 5Cleveland Clinic, Cleveland, OH, 6Cole Eye Institute/Cleveland Clinic, Cleveland, OH, 7Children's Mercy Kansas City, Kansas City, MO, 8Boston Children's Hospital, Boston, 9Boston Children's Hospital, Boston, MA, 10Cincinnati Children's Hospital, Cincinnati, OH

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2026

Keywords: Eye Disorders, Gene Expression, Juvenile idiopathic arthritis

Session Information

Date: Sunday, November 8, 2026

Title: (0104-0110) Pediatric Rheumatology - Basic and Translational Science Poster A

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Methotrexate (MTX) is the recommended first-line treatment for children with non-infectious uveitis (NIU), with treatment failure rates as high as 50%. Because therapeutic response may take 3-6 months, delays can lead to prolonged corticosteroid exposure and irreversible ocular complications.  Gene expression predictors of MTX response are lacking, and prior studies in inflammatory arthritis patients have produced conflicting results. We, therefore, sought to explore predictors of response to MTX using whole blood transcriptional profiling.

Methods: For this prospective, multicenter study (OptiMTX), we included patients diagnosed with any type of NIU at < 18 y/o starting MTX and pediatric controls (HC). Blood samples were collected within 4 weeks of starting MTX (baseline) and a follow up visit at 3/6/12 months. They were grouped by MTX response as: responders (MTX-R) and inadequate responders (MTX-IR) based on addition of biologic therapy. We compared: 1) baseline samples of MTX-R v MTX-IR, 2) NIU v HC, and 3) baseline vs time of IR. 3mL of blood was drawn directly into the Tempus Blood RNA Tube, and total RNA was extracted via Tempus™ Spin RNA Isolation Kit (Applied Biosystems). We performed globin and rRNA depletion prior to library construction, and equimolar pooled libraries were sequenced on Illumina NovaSeq X with ~60M reads per sample. Samples were aligned using the NF-Core RNAseq pipeline (v3.18.0) for bulk samples, built inside a NextFlow scaffold (v24.10.1). Filtered reads were aligned to the hg38 reference genome with STAR (2.6.1d) and counted with Salmon (1.10.3). A log2 fold change cutoff ≥0.4 and pvalue ≤0.05 were used to determine statistical significance.

Results: There were 20 patients (14 MTX-IR, 6 MTX-R) and 5 HC. Examining baseline gene expression signatures, there was substantial patient-level heterogeneity. Comparing all patients to healthy controls, we observed an upregulated gene expression signature enriched in pathways including heme metabolism (p=0.019), chemokine receptors (p=0.047), and IL-10 signaling (p=0.044). When examining baseline signatures between MTX-R and MTX-IR, the most enriched gene pathway was interferon alpha response (p=0.14) including IFI27 and TRIM14. Other positively enriched gene pathways included regulation of extrinsic apoptotic signaling and positive regulation of erythrocyte differentiation. Finally, we examined changes in transcriptional profiles at follow-up compared to baseline, regardless of treatment response, and observed a strong downregulated signature including CXCL10.

Conclusion: Whole blood transcriptional profiles from children with NIU demonstrate substantial variability. This pilot study nominates genes and pathways associated with MTX response including interferon alpha pathway. Further work will validate these findings and integrate gene expression signatures with other clinical and imaging features of NIU to support a predictive model of MTX response.


Disclosures: G. Schulert: SOBI, 12,; T. Do: None; A. Kuenzi Davis: None; E. Straus: None; A. Jagger: None; M. Chang: Attovia Therapeutics, 12,, 12, , 12, ; M. Altaye: None; V. Utz: None; H. Brunner: AbbVie, 12,, 12, , AstraZeneca-Medimmune, 12,, Biogen, 12,, Boehringer-Ingelheim, 12,, Bristol-Myers Squibb, 12,, Celgene, 12,, Eli Lilly, 12,, EMD Serono, 12,, F. Hoffmann-La Roche, 12,, Genzyme, 12,, GlaxoSmithKline, 12,, Johnson & Johnson, 12,, Merck, 12,, Novartis, 12,, Pfizer, 12,, Roche, 12,, R-Pharm, 12,, Sanofi, 12,; A. Zeft: Lixte, 12,, Merck/MSD, 12,, Opko Health, 12,, Teva, 12,; S. Srivastava: AbbVie/Abbott, 12,, Genentech, 12,, 12, , Merck/MSD, 12,, Novartis, 12,, Roche, 12,; E. Stahl: Sydnexis, 12,; A. Cooper: None; B. Nihalani-Gangwani: None; M. Lo: None; M. Quinlan-Waters: None; A. Duell: None; S. Angeles-Han: Cabaletta Bio, 12,.

To cite this abstract in AMA style:

Schulert G, Do T, Kuenzi Davis A, Straus E, Jagger A, Chang M, Altaye M, Utz V, Brunner H, Zeft A, Srivastava S, Stahl E, Cooper A, Nihalani-Gangwani B, Lo M, Quinlan-Waters M, Duell A, Angeles-Han S. Gene expression signatures as predictors of response to methotrexate in pediatric non-infectious uveitis (NIU). [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/gene-expression-signatures-as-predictors-of-response-to-methotrexate-in-pediatric-non-infectious-uveitis-niu/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gene-expression-signatures-as-predictors-of-response-to-methotrexate-in-pediatric-non-infectious-uveitis-niu/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology